{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:42:44Z","timestamp":1790991764707,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00259-022-05704-0","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T10:03:42Z","timestamp":1644228222000},"page":"2342-2351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The diagnostic accuracy and clinical impact of FDG-PET\/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma"],"prefix":"10.1007","volume":"49","author":[{"given":"Jesper A. S.","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders D.","family":"Spatzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie H.","family":"Vilstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Grupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paw C.","family":"Holdgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oke","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene G.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"5704_CR1","unstructured":"Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz AG, Greene FL. AJCC cancer staging manual. 7th Editio. Springer New York; 2010."},{"key":"5704_CR2","doi-asserted-by":"publisher","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long G V., Ross MI, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","DOI":"10.3322\/caac.21409"},{"key":"5704_CR3","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, Van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1884\u2013901. https:\/\/doi.org\/10.1093\/annonc\/mdz411.","journal-title":"Ann Oncol"},{"key":"5704_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(15)70122-1.","journal-title":"Lancet Oncol"},{"key":"5704_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/nejmoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335. https:\/\/doi.org\/10.1056\/nejmoa1709030.","journal-title":"N Engl J Med"},{"key":"5704_CR6","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/nejmoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III Melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355. https:\/\/doi.org\/10.1056\/nejmoa1611299.","journal-title":"N Engl J Med"},{"key":"5704_CR7","unstructured":"Opdivo - information til sundhedsfaglige [Opdivo - information for healthcare professionals] n.d. https:\/\/pro.medicin.dk\/Medicin\/Praeparater\/7799#a380 (accessed May 26, 2021)."},{"key":"5704_CR8","doi-asserted-by":"publisher","unstructured":"Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, et al. Appropriate use criteria for 18 F-FDG PET\/CT in restaging and treatment response assessment of malignant disease 2017. https:\/\/doi.org\/10.2967\/jnumed.117.197988.","DOI":"10.2967\/jnumed.117.197988"},{"key":"5704_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129\u201342. https:\/\/doi.org\/10.1093\/jnci\/djq455.","journal-title":"J Natl Cancer Inst"},{"key":"5704_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2020.02.024","volume":"131","author":"E Chorti","year":"2020","unstructured":"Chorti E, Kanaki T, Zimmer L, Hadaschik E, Ugurel S, Gratsias E, et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis. Eur J Cancer. 2020;131:18\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2020.02.024.","journal-title":"Eur J Cancer"},{"key":"5704_CR11","unstructured":"Donia M, Luczak A, \u00d8llegaard T, Bastholt L, Larsen M, H\u00f6lmich L, et al. Medicinr\u00e5dets vurdering af klinisk merv\u00e6rdi for nivolumab til adjuverende behandling af moderm\u00e6rkekr\u00e6ft [The Danish Medicines Council\u2019s assesment of clinical benefit of nivolumab for adjuvant treatment of melanoma] 2018."},{"key":"5704_CR12","unstructured":"Dansk Melanom Gruppe. Adjuverende behandling af melanom [Adjuvant treatment of melanoma] 2021:8\u201311. https:\/\/www.dmcg.dk\/siteassets\/forside\/kliniske-retningslinjer\/godkendte-kr\/dmg\/dmg_adj_beh_melanom_admgodk070121.pdf (accessed June 7, 2021)."},{"key":"5704_CR13","unstructured":"Sundhedsstyrelsen. Pakkeforl\u00f8b for moder-maerkekraeft i huden For fagfolk [Standardised treatment regimens for cutaneous melanoma for medical professionals]. 4.0. 2020."},{"key":"5704_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cpet.2017.05.002","volume":"12","author":"E Mena","year":"2017","unstructured":"Mena E, Sanli Y, Marcus C, Subramaniam RM. Precision Medicine and PET\/CT in Melanoma HHS Public Access. PET Clin. 2017;12:449\u201358. https:\/\/doi.org\/10.1016\/j.cpet.2017.05.002.","journal-title":"PET Clin"},{"key":"5704_CR15","doi-asserted-by":"publisher","unstructured":"Ellebaek E, Svane IM, Schmidt H, Haslund CA, Donia M, Hoejberg L, et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol 2021;73. https:\/\/doi.org\/10.1016\/j.canep.2021.101943.","DOI":"10.1016\/j.canep.2021.101943"},{"key":"5704_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"5704_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Biomed Inform"},{"key":"5704_CR18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/nejmoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801. https:\/\/doi.org\/10.1056\/nejmoa1802357.","journal-title":"N Engl J Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05704-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05704-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05704-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:26:55Z","timestamp":1744154815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05704-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5704"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05704-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"2 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lars Bastholt received salary for advisory position for Bristol Myers Squibb. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}